Zevra Therapeutics Inc (ZVRA) marks a successful transition to a commercial stage with MyPIFA's launch, despite financial ...

It’s been just six months since Zevra Therapeutics scored an FD | Niemann-Pick disease type C therapy Miplyffa became ...

Q4 2024 Earnings Call Transcript March 11, 2025 Zevra Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0 ...

FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of 2024Entered into asset purchase agreement ...

ITF, IntraBio and Orchard are among the companies that have won FDA nods in the past year for Duchenne muscular dystrophy, ...

Several rare disease patient populations received their first-ever FDA-approved drug since Rare Disease Day last year, ...

FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of 2024 Entered into asset purchase agreement for sale of PRV for $150 million Company to host confer ...

Zevra has sold its US Food and Drug Administration (FDA) priority review voucher (PRV) for $150m to an undisclosed party.

The data included on our label shows MIPLYFFA in combination with miglustat, halted disease progression through 12 months, demonstrated by more than a two point improvement in patients receiving ...

MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and ...